DrugRisk Update: Lawsuits Allege Researcher Hired By Pradaxa Maker Failed to Report Side Effects

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa lawsuit
The resource center has added research indicating patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding.

Chicago, IL (PRWEB) March 07, 2014

The prescription drug safety center DrugRisk.com is announcing updated legal news on the site for patients taking the blood thinner Pradaxa. In a new report, lawsuits allege the research institute that conducted trails of Pradaxa for its FDA approval failed to disclose side effects like internal bleeding*.

DrugRisk is a free resource for those taking popular prescription drugs. The site provides the latest recalls, safety alerts, research and litigation news, so visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.

Pradaxa was approved in 2010 and is prescribed to prevent blood clots and strokes in patients with atrial fibrillation. Experts disagree, however, whether it increases risks of internal bleeding.

The resource center has added research indicating patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***.

The FDA recently announced it will conduct a new study comparing the safety Pradaxa and the traditional blood thinning medication warfarin****.

Due to the number of families that have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated in a special federal multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, Drugrisk has learned the lawsuit has named the clinic that conducted trials for Boehringer Ingelheim used for Pradaxa’s FDA approval, Population Health Research Institute, alleging they failed to properly conduct the trial, maintain data or report serious adverse events*.

Anyone who suffered internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the complex nature of these cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*The Spectator, 2/15/14; thespec.com/news-story/4369907-trial-and-errors-mac-hhs-sued-over-drug-safety/; Suzanne Mackiewicz, on behalf of the Estate of Malachy Higgins, deceased, and Suzanne Mackiewicz, Individually v. Boehringer Ingelheim Pharmaceuticals, Inc., et al, Case No.: 3:13-cv-50167- DRH-SCW (Southern Dist. Illinois)
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/


Contact